Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and diagnostics. The company also provides a complementary liquid biopsy assay that analyzes various human genes versus. It serves approximately 45 biopharmaceutical customers, including a range of pharmaceutical companies. The company was founded in 2011 and is headquartered in Menlo Park, California.
Industry, Sector and Symbol
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone650-752-1300
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees147
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable
Personalis (NASDAQ:PSNL) Frequently Asked Questions
What is Personalis' stock symbol?
Personalis trades on the NASDAQ under the ticker symbol "PSNL."
How were Personalis' earnings last quarter?
Personalis (NASDAQ:PSNL) posted its earnings results on Tuesday, August, 13th. The company reported ($0.89) EPS for the quarter, missing the consensus estimate of ($0.31) by $0.58. The business had revenue of $15.80 million for the quarter, compared to analysts' expectations of $14.92 million. The firm's revenue was up 79.5% on a year-over-year basis. View Personalis' Earnings History.
When is Personalis' next earnings date?
What guidance has Personalis issued on next quarter's earnings?
Personalis issued an update on its FY 2019 earnings guidance on Tuesday, August, 13th. The company provided EPS guidance of for the period. The company issued revenue guidance of $60-62 million, compared to the consensus revenue estimate of $59.07 million.
What price target have analysts set for PSNL?
5 equities research analysts have issued 12-month target prices for Personalis' stock. Their predictions range from $22.00 to $29.00. On average, they anticipate Personalis' stock price to reach $27.00 in the next year. This suggests a possible upside of 126.9% from the stock's current price. View Analyst Price Targets for Personalis.
What is the consensus analysts' recommendation for Personalis?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Personalis in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Personalis.
Has Personalis been receiving favorable news coverage?
Press coverage about PSNL stock has been trending somewhat positive this week, according to InfoTrie Sentiment. InfoTrie scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Personalis earned a media sentiment score of 0.8 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Personalis.
Are investors shorting Personalis?
Personalis saw a increase in short interest in September. As of September 30th, there was short interest totalling 809,600 shares, an increase of 57.7% from the August 30th total of 513,400 shares. Based on an average trading volume of 351,800 shares, the days-to-cover ratio is currently 2.3 days. Currently, 5.0% of the company's stock are short sold. View Personalis' Current Options Chain.
Who are some of Personalis' key competitors?
Some companies that are related to Personalis include Veracyte (VCYT), CareDx (CDNA), RadNet (RDNT), Castle Biosciences (CSTL), Fulgent Genetics (FLGT), Celcuity (CELC), Enzo Biochem (ENZ), Psychemedics (PMD), Miragen Therapeutics (MGEN), PotNetwork (POTN), Biocept (BIOC), Avant Diagnostics (AVDX), CBA Florida (CBAI), Cancer Genetics (CGIX) and First Choice Healthcare Solutions (FCHS).
What other stocks do shareholders of Personalis own?
Who are Personalis' key executives?
Personalis' management team includes the folowing people:
- Mr. John West, Co-Founder, CEO, Pres & Director (Age 62)
- Prof. Russ B. Altman M.D., Ph.D., Co-Founder and Member of Clinical & Scientific Advisory Board
- Mr. Euan A. Ashley, Co-Founder and Member of Clinical & Scientific Advisory Board
- Dr. Atul Butte, Co-Founder and Member of Clinical & Scientific Advisory Board
- Dr. Michael Snyder Ph.D., Co-Founder and Member of Clinical & Scientific Advisory Board
When did Personalis IPO?
(PSNL) raised $100 million in an IPO on Thursday, June 20th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen and Company acted as the underwriters for the IPO and Oppenheimer was co-manager.
When does the company's lock-up period expire?
Personalis' lock-up period expires on Tuesday, December 17th. Personalis had issued 7,921,500 shares in its initial public offering on June 20th. The total size of the offering was $134,665,500 based on an initial share price of $17.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the expiration of the lock-up period.
How do I buy shares of Personalis?
Shares of PSNL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Personalis' stock price today?
One share of PSNL stock can currently be purchased for approximately $11.90.
How big of a company is Personalis?
What is Personalis' official website?
How can I contact Personalis?
Personalis' mailing address is 1330 O`BRIEN DRIVE, MENLO PARK CA, 94025. The company can be reached via phone at 650-752-1300 or via email at [email protected]
MarketBeat Community Rating for Personalis (NASDAQ PSNL)
MarketBeat's community ratings are surveys of what our community members think about Personalis and other stocks. Vote "Outperform" if you believe PSNL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PSNL will underperform the S&P 500 over the long term. You may vote once every thirty days.
